It is now widely recognized that breast cancer comprises heterogeneous subtypes that require different treatment approaches.15 The successful development of trastuzumab, the first drug to target HER2-positive cancer, validates the concept that we can improve outcomes by treating an underlying molecular driver. Here, ERBB2 is linked to cancer.